We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Handheld Device Shown to Detect Cancer

By HospiMedica staff writers
Posted on 30 Jul 2003
A handheld device based on military technology may represent a portable, quick, noninvasive way to detect cancer.

The lightweight plastic baton, called TRIMprob (tissue resonance interaction method), is similar to the metal detectors used to examine airline passengers. More...
The baton contains an antenna that generates an electromagnetic field at very low power, interacting with tissues at the microscopic level. A computer linked to the probe analyzes the amount of interference at different frequencies and displays results in real-time in an easily understandable graphical format. The TRIMprob analyzes the condition of tissues and organs, detects and localizes pathologies ranging from inflammatory conditions to cancer, and finds them at an early stage. The baton can be used while patients are dressed and comfortable, providing immediate results.

In clinical trials at the San Carlo Borromeo Hospital in Milan (Italy), TRIMprob was able to predict prostate tumors in 93% of cases that were later confirmed by biopsy. Trials are now underway in other Italian hospitals for breast, lung, colon-rectal, liver, and stomach abnormalities.

TRIMprob is based on patented technology developed by physicist Clarbruno Vedruccio for Galileo Avionica, a subsidiary of Finmeccanica S.p.A., (Rome, Italy; www.finmeccanica.it), Italy's largest defense and aerospace group. After designing a detector for nonmetallic land mines and plastic explosives, Dr. Vedruccio decided he might be able to locate diseased tissue in people. When tests were carried out, they were very encouraging.

"In a short period of time and with a noninvasive procedure, we can discover or exclude a neoplastic prostate pathology. It is particularly useful for mass screenings as the first approach to assess nonrisk patients from those who need more refined searches,” said Dr. Ulrico Jacobellis, chief of the department of urology at the Polyclinic Hospital (Bari, Italy), affiliated with the Lahey Clinic in Burlington (MA, USA). Dr. Jacobellis is also an adjunct professor of urology at the Tufts University School of Medicine.




Related Links:
Finmeccanica

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Patient Preoperative Skin Preparation
BD ChloraPrep
New
Patient Monitoring System
AlarmSense
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Health IT

view channel
Photo courtesy of Adobe Stock

Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings

Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.